TrialCancer immunology, immunotherapy : CII2011

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

Joshua M Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.